Images List Premium Download Classic

Antibodies

Antibodies-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Expression constructs and methods for selecting host cells expressing polypeptides
Glenmark Pharmaceuticals S.a.
December 07, 2017 - N°20170350886

The invention relates to an expression construct for the soluble expression of polypeptides in host cells and for the expression of polypeptides on the surface of host cells, using alternative splicing. The amount of cell membrane expression of polypeptides such as antibodies, antibody fragments and bispecific antibodies can be correlated directly to the amount of soluble polypeptide expressed. In the ...
Methods of diagnosing chronic obstructive pulmonary disease (copd) using novel molecular biomarkers
Transgenion-international Institute For Regenerative Translational Medicene Gmbh
December 07, 2017 - N°20170349947

The present invention relates to in vitro methods for the diagnosis of chronic obstructive pulmonary disease (copd), wherein the expression of the marker gene tmsb15a is determined. In particular, the invention relates to an in vitro diagnostic method of assessing the susceptibility of a subject to develop progressive copd involving the appearance of irreversible lung damage, wherein the expression ...
Multispecific antibodies
Hoffmann-la Roche Inc.
December 07, 2017 - N°20170349669

The present invention relates to multispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies and uses thereof.
Antibodies Patent Pack
Download 1876+ patent application PDFs
Antibodies Patent Applications
Download 1876+ Antibodies-related PDFs
For professional research & prior art discovery
inventor
  • 1876+ full patent PDF documents of Antibodies-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Anti-cd52 antibodies
Genzyme Corporation
December 07, 2017 - N°20170349665

Anti-human cd52 antibodies and antigen-binding fragments thereof are provided. Also provided are isolated nucleic acids, recombinant vectors and host cells for making the antibodies and fragments. The antibodies and fragments can be used in therapeutic applications to treat, for example, autoimmune diseases, cancer, and graft rejection.
Antagonistic anti-ox40l antibodies and methods of their use
Baylor Research Institute
December 07, 2017 - N°20170349661

Described herein are methods and compositions for treating autoimmunity and inflammatory conditions without non-specific suppression of the host immune system. In particular, the anti-ox40l antibodies described herein are unique in that they not only inhibit the differentiation of inflammatory t cells but also promote the generation and function of regulatory t cells by inducing il-10 and inhibiting tnf-...
Bispecific antibodies that bind cd123 and cd3
Xencor. Inc.
December 07, 2017 - N°20170349660

The present invention is directed to novel bispecific anti-cd123 x anti-cd3 antibodies.
Antibodies Patent Pack
Download 1876+ patent application PDFs
Antibodies Patent Applications
Download 1876+ Antibodies-related PDFs
For professional research & prior art discovery
inventor
  • 1876+ full patent PDF documents of Antibodies-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Bispecific antibodies that bind cd20 and cd3
Xencor, Inc.
December 07, 2017 - N°20170349657

The present invention is directed to methods of administrating bispecific anti-cd20×anti-cd3 antibodies.
Methods for treating spinal cord injury and pain
Abbvie Deutschland Gmbh & Co. Kg
December 07, 2017 - N°20170349653

Disclosed herein are anti-rgma antibodies and methods of using these antibodies to treat spinal cord injury, including promoting axonal regeneration, functional recovery, or both and to treat pain, including neuropathic pain arising from spinal cord injury.
Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
Aerpio Therapeutics, Inc.
December 07, 2017 - N°20170349649

Antibodies and antigen binding fragments thereof that bind to human protein tyrosine phosphatase beta (hptpβ), and uses thereof.
Compositions and methods for treating and preventing staphylococcus aureus infections
Xbiotech, Inc.
December 07, 2017 - N°20170349648

Antibodies having fab regions that specifically bind to staphylococcus aureus protein a are capable of mediating opsinization of staphylococcus aureus bacteria despite their expression of antibody-neutralizing protein a. These antibodies and antigen-binding fragments thereof can be used in methods of treating and/or preventing staphylococcus aureus infections.
Compositions and methods for treatment of cytomegalovirus
Variation Biotechnologies Inc.
December 07, 2017 - N°20170349634

The present disclosure provides compositions and methods useful for treating hcmv infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (vlps) which comprise one or more moloney murine leukemia virus (mmlv) core proteins and include one or more hcmv epitopes, such as, for example, from hcmv envelope glycoproteins gb and/...
Novel recombinant adeno-associated virus capsids resistant to pre-existing human neutralizing antibodies
The Board Of Trustees Of The Leland Stanford Junior University
December 07, 2017 - N°20170348433

The present invention relates to variant aav capsid polypeptides, wherein the variant capsid polypeptides exhibit an enhanced neutralization profile, increased transduction and/or tropism in human liver tissue or hepatocyte cells (i. E., human hepatocyte cells), or both, as compared non-variant parent capsid polypeptides.
Pharmaceutical formulations and methods of use thereof
Immunogen, Inc.
December 07, 2017 - N°20170348427

This disclosure is directed to antibody-drug conjugates. More specifically, this disclosure is directed to compositions comprising (i) antibody-drug conjugates comprising benzodiazepines, and (ii) a small hydrophobic molecule, methods of treatment using the compositions, and methods of formulating the compositions. Furthermore, this disclosure is directed to methods of reducing reversible self-association in antibodies and in antibody-drug conjugates.
Antibodies Patent Pack
Download 1876+ patent application PDFs
Antibodies Patent Applications
Download 1876+ Antibodies-related PDFs
For professional research & prior art discovery
inventor
  • 1876+ full patent PDF documents of Antibodies-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Adjuvants useful for stimulation of immunity to tumor endothelial cells
Batu Biologics, Inc.
December 07, 2017 - N°20170348388

Adjuvants acting at the level of antigen presentation useful for stimulation of specific immunity against tumor endothelial cells. In one embodiment the invention teaches the use of activation of specific antigen presenting cell programs to selectively induce cytotoxic t cells and antibodies with complement activating ability while not evoking antigenic responses that potentially stimulate angiogenesis or growth of tumor endothelial ...
Mt-45 immunodetection
Randox Laboratories Ltd.
November 30, 2017 - N°20170343570

Components for enabling immunodection of mt-45 are described including immunogens, antibodies derived from the immunogens, immunoassay methods, detecting agents and kits.
Antibodies to olanzapine haptens and use thereof
Janssen Pharmaceutica Nv
November 30, 2017 - N°20170343569

Disclosed is an antibody which binds to olanzapine, which can be used to detect olanzapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of olanzapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.
Method for the determination of anti-drug antibodies against an effector function suppressed human or humanized ...
Hoffmann-la Roche Inc.
November 30, 2017 - N°20170343560

Herein is reported an anti-drug antibody immunoassay for the determination of the presence of an anti-drug antibody against an effector function suppressed human or humanized drug antibody in a sample comprising the incubation of a sample comprising mammalian blood serum with full length human fcgamma receptor i or an fc-region binding fragment thereof so that a complex between the anti-drug ...
Methods and compositions for single chain variable region enox2 antibodies for cancer detection and diagnosis
Mor-nuco Enterprises, Inc.
November 30, 2017 - N°20170343555

Cancers of different cellular or tissue origins express different enox2 cancer isoforms or combinations of isoforms and shed these proteins into the circulation. Herein are disclosed methods both for cancer detection and diagnosis of particular origin, based on the patterns and molecular weights of the isoforms which allow the identification of the cell type and or tissue of origin of ...
Novel anti-cd38 antibodies for the treatment of cancer
Sanofi
November 30, 2017 - N°20170343550

Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to cd38, are capable of killing cd3830 cells by apoptosis, antibody-dependent cell-mediated cytotoxicity (adcc), and/or complement-dependent cytotoxicity (cdc). Said antibodies and fragments thereof may be used in the treatment of tumors that express cd38 protein, such as multiple myeloma, chronic ...
Method of prognosing and predicting breast cancer recurrence, markers employed therein and kit thereof
Oncostem Diagnostics (mauritius) Pvt. Ltd.
November 30, 2017 - N°20170343548

The present disclosure relates to a method of prognosing and predicting breast cancer recurrence in patients, more particularly, the present disclosure relates to a method of prognosing which stratifies early stage er+/pr+ and her2− breast cancer patients with invasive ductal/lobular carcinoma of the breast into low risk or high risk for breast cancer recurrence by employing an ...
Specific monoclonal antibodies of the antigen m of the human metapneumovirus (hmpv) and use thereof ...
Pontificia Universidad Catolica De Chile
November 30, 2017 - N°20170343546

The invention relates to murine monoclonal antibodies corresponding to monoclonal antibodies secreted by cell lines of hybridomas denominated 3g8/c11 and 7g4/a12, and which react against the antigen m of hmpv. Said antibodies do not compete with each other for the binding site for binding to the antigen, nor do they impede the simultaneous binding thereof to the antigen. ...
Loading